KYV-101 IIT data demonstrate promising clinical activity, including robust CAR T penetration into the central nervous system (CNS) and improved…
ARTIOS Phase IIIb, open-label, single-arm, prospective study showed a substantial reduction in disease activity in people with relapsing multiple sclerosis…
OCREVUS subcutaneous maintains consistent benefit-risk profile after two years New late-breaking data confirms OCREVUS significantly reduces disability progression in adults…
WASHINGTON, Sept. 23, 2025 /PRNewswire/ -- As the medication experts, APhA affirms there has been no new evidence in two…
Study led by CureShankAims to characterize the direct and indirect burden of PMS to patients, caregivers, and US healthcare system…
Updates to McDonald Diagnostic Criteria for MS published NEW YORK, Sept. 18, 2025 /PRNewswire/ -- The McDonald Diagnostic Criteria for…
Once-daily oral brepocitinib 30 mg demonstrated clinically meaningful and statistically significant improvement compared to placebo on the primary endpoint and…
PHILADELPHIA, PA / ACCESS Newswire / September 16, 2025 / TruMerit, a global leader in healthcare workforce development, today launched…
MIRA advances Ketamir-2 in the clinic for neuropathic pain while broadening development into neuropsychiatric disorders such as PTSD MIAMI, FLORIDA…
Clinical data shows that BrainsWay’s new accelerated stimulation protocol is comparable to standard Deep TMS in depression score improvement, response…